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Abstract
Context—Although the cross-sectional association between cancer-related pain and disability is
well-established, their longitudinal relationship has been less studied.
Objectives—Data from the Indiana Cancer Pain and Depression (INCPAD) trial was analyzed to
determine whether baseline cancer-related pain and changes in pain over time predict disability
over 12 months.
Methods—A total of 274 cancer survivors with cancer-related pain were accrued in the INCPAD
trial. Data were collected at baseline, 1, 3, 6, and 12 months by interviewers blinded to treatment
arm. Disability outcomes included a continuous measure (Sheehan Disability Scale score) and a
categorical measure (≥ 14 days in the past four weeks with a ≥ 50% reduction in usual activities).
Predictor variables, operationalized by the Brief Pain Inventory, included baseline pain severity
and changes in pain severity scores between each time point. Multivariable analyses were
conducted adjusting for treatment group, baseline disability, and selected covariates including
depression.
Results—Baseline pain severity did not predict disability outcomes at 12 months. However,
improvement in pain severity predicted less disability over 12 months both in terms of Sheehan
Disability Scale scores (b = −0.17, t = −5.33, P< 0.001) and ≥ 14 disability days in the past month
(odds ratio = 0.85; 95% confidence interval, 0.79–0.93; P< 0.001).
Conclusion—Disability over 12 months in patients with cancer-related pain is predicted by
changes in pain severity over time. Results suggest that effective pain management may reduce
subsequent disability among cancer survivors.
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Introduction
The National Cancer Institute has determined that an individual becomes a cancer survivor
at the time of cancer diagnosis and remains a cancer survivor through the balance of his or
her life.1 In 2006, it was estimated that there were 11.4 million cancer survivors,
representing approximately 3.8% of the U.S. population.2 Cancer survivors are at risk for
disability because they are more vulnerable to other cancers, cardiovascular diseases,
osteoporosis, diabetes mellitus, and accelerated functional decline.3
Comprehensive assessment of the impact of cancer and its treatment typically includes
symptoms experienced, physical functioning, and quality of life.4–7 However, little attention
has been paid to factors that influence disability after cancer is diagnosed. Previous cancer
survivorship studies have defined disability in a limited way, such as physical activity
limitation8–11 or work impairment.12, 13 It is necessary to understand how cancer survivors
can function reasonably well both socially and at work. Disability can be broadly defined as
impairment in family roles, social roles, and work roles and responsibilities.14, 15 While
some cancer survivors, even those who experience severe symptoms, are able to maintain, or
return to, their usual roles and responsibilities, others with less severe symptoms can be
quite disabled.16, 17 Therefore, treatment must focus not only on control of symptoms for
cancer survivors, but also on reducing morbidity resulting from disability.
Research has shown that symptoms are positively related to disability.15, 17–19 Pain, a highly
prevalent symptom in cancer survivors, has the potential to be linked with disability. From
33% to 64% of cancer survivors experience pain, and studies have shown that cancer pain is
undertreated in up to 82% of survivors.20, 21 It also has been shown that cancer survivors
with more severe pain have lower Karnofsky Performance scores.22, 23, 24
The Indiana Cancer Pain and Depression (INCPAD) study is a randomized clinical trial
implemented among survivors who have various types and phases of cancer, with a 12-
month telephone care management intervention targeted to improve pain and/or
depression.25 Cross-sectional analyses of baseline data showed that participants with more
severe cancer-related pain reported greater disability.26 However, the relationship between
changes in pain over time and subsequent disability is less well-established. The most recent
symptom management model has shown that the temporal aspect of symptoms must be
embraced in future research.27 The repeated assessment of outcomes over 12 months in the
INCPAD trial provided a unique opportunity to examine the longitudinal relationship
between cancer-related pain and disability. Therefore, we conducted this secondary analysis
to address the following research questions:
1. Does cancer-related pain in cancer survivors on entry to the INCPAD trial
(baseline) predict disability at 12 months?
2. Do changes in their cancer-related pain predict subsequent disability over 12
months?
Methods
Sample and Setting
The design, intervention, and participant characteristics of the INCPAD study have been
described in previous studies.25, 26 Briefly, patients from 16 urban and rural outpatient
oncology clinics in Indiana from March 2006 through August 2008 were screened for the
presence of cancer-related pain or depression. Eligibility criteria required that patients be
experiencing moderately severe cancer-related pain (a Brief Pain Inventory [BPI] worst pain
severity score ≥ 6), or depression (a Patient Health Questionnaire nine-item depression scale
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[PHQ-9] score ≥ 10, with depressed mood and/or anhedonia).28–31 Cancer-related pain was
defined as pain occurring in the region of the primary tumor or cancer metastases and/or
occurring after the onset of cancer treatment. This pain had to be persistent despite the
patient trying at least one pain medication. Excluded were patients who: (a) did not speak
English; (b) had moderately severe cognitive impairment as defined by a six-item cognitive
screener;32 (c) had schizophrenia or other psychoses; (d) had a disability claim currently
being adjudicated for pain; (f) were pregnant; (g) were in hospice care; or (h) had pre-
existing pain conditions unrelated to cancer.
Of the 405 cancer patients enrolled in the INCPAD trial, 96 had cancer-related pain only,
131 had depression only, and 178 had both cancer-related pain and depression. Block
randomization was stratified by symptom type (cancer-related pain only, depression only, or
both cancer-related pain and depression) resulting in 202 being in the intervention group and
203 being in the control group. For the current secondary analysis, only data from 274
participants who had cancer-related pain (with or without depression) were included: 137 in
the intervention group and 137 in the control group. The intervention group received
telephone care management (telecare) focusing on optimizing medications to treat their
cancer-related pain and/or depression, while the control group received usual oncology care.
Telecare Intervention
Details of the telecare intervention have been described previously.25 In brief, participants in
the intervention group underwent a schedule of automated symptom monitoring by
telephone or over the Internet for 12 months. Participants also received several scheduled
calls from a centralized nurse care manager during treatment initiation as well as subsequent
calls based upon automated monitoring trend reports. The care manager nurse was
supervised by a physician specialist who met in weekly case management conferences to
discuss treatment plans for newly-enrolled patients as well as patients who needed further
adjustments in therapy. Recommendations for optimizing analgesics (for pain) or
antidepressants (for depression) were provided to the participant’s primary oncologist who
was responsible for prescribing all medications. The treatment goal for cancer-related pain
was at least a 30% reduction in the BPI score. The effects of the telecare intervention have
been published.33 Our current analysis controlled for intervention group assignment.
Data Collection
Data were collected through phone interviews at baseline (T0), one month (T1), three
months (T3), six months (T6), and 12 months (T12). Research assistants conducting the
interviews were blinded to group assignment.
Measures
Outcome Variables—Disability was measured using the Sheehan Disability Scale (SDS)
and Total Disability Days (TDD). The SDS consists of three items asking how much the
participant’s health condition has interfered with his/her family life, social life, and work
over the past month on a scale of 0 (not at all) to 10 (unable to carry on any activities). The
SDS score was a mean of these three items; higher scores reflect greater disability. The
construct and criterion validity of the SDS are well established18 and internal reliability in
the INCPAD study was 0.82.25 TDD was assessed with a single item that asked participants
to indicate the number of days during the preceding four weeks that they were either in bed
or had to reduce work or usual activities by 50% or more.34, 35
Independent Variables—Cancer-related pain was the major predictor variable of interest
and was measured using the Brief Pain Inventory (BPI) severity scale, which asks
participants to rate their pain at its worst, its least, and on average in the past week, as well
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as their current pain on a 0 (no pain) to 10 (pain as bad as you can imagine) scale.28,36 The
mean of the four items was determined, with higher scores reflecting more severe pain. The
BPI had good internal reliability (Cronbach’s α = 0.79) in the INCPAD study.25
Depression at baseline was measured as an important covariate using the Hopkins Symptom
Checklist 20-item (HSCL-20) depression scale.37 The 20 items ask how much participants
had been distressed by various symptoms of depression in the previous four weeks on a 0
(not at all) to 5 (extremely) scale. The mean of these items is determined, with higher scores
reflecting more severe depression. The HSCL-20 had good internal reliability (α = 0.79) in
INCPAD.25
Other potential covariates included demographics (age, gender, race, marital status,
education, job status, and income) and baseline clinical factors (medical comorbidity, type
of cancer, and phase of cancer). Age, gender, race, marital status, education, job status, and
income were collected using a demographic survey. The Socioeconomic Disadvantage
(SED) Index is a composite measure, which assigns one point each for low education (“less
than high school” = 1 point), unemployment (“unable to work due to health or disability” =
1 point), or low income (“not enough to make ends meet” = 1 point).38 Medical comorbidity
was assessed using a checklist of eight diseases. Type of cancer and phase of cancer were
extracted from medical records. Phase of cancer was determined by if participants were
newly-diagnosed, had maintenance or disease-free status, or had recurrent or progressive
cancers.
Statistical Analysis
The two disability outcome variables in the analysis were the SDS score and TDD. The SDS
was a continuous variable. The total number of disability days in the past four weeks, TDD,
ranged from 0 to 28. However, the distribution of TDD was bimodal (U shaped). We,
therefore, recoded TDD as a binary variable (< 14 days = 0; ≥ 14 days =1).
The first research question asked whether cancer-related pain at baseline of the INCPAD
trial predicted disability at 12 months. The predictor variable was the baseline BPI severity
score. Of the 274 participants who provided baseline data, 180 completed 12-month
interviews (the remainder had died, dropped out, or were unable to be contacted). Data from
these 180 participants were used to develop two models for the first research question. A
multivariable linear regression analysis was performed to examine the SDS at 12 months.
We initially conducted bivariate analyses to determine which covariates (i.e., those with a P-
value of less than 0.20) to adjust for in the multivariable model. We then ran the full model
with baseline BPI severity as a predictor while adjusting for the covariates, baseline SDS,
and intervention group factor. For TDD at 12 months, a logistic regression model was used.
We followed the same two steps described above for this second model as well.
The second research question asked whether changes in cancer-related pain predicted
disability at the subsequent time point over the 12 months. Figure 1 diagrams the repeated
measures modeling. The outcome variables were SDS and TDD at one month, three months,
six months, and 12 months. Predictor variables were BPI severity changes between each
time point over 12 months (T0-T1: between baseline and one month; T1-T3: between one
month and three months; T3-T6: between three months and six months; and T6-T12:
between six months and 12 months). Data from available participants at each time point
were examined in the linear mixed effects repeated measures for SDS and generalized linear
mixed effects repeated measures for TDD. In this analysis, random subject effect was
incorporated into the model to accommodate the potential correction among the repeatedly
measured outcomes within the subject. For model selection, we initially performed bivariate
analyses to determine which covariates were potentially significant (i.e., P-value < 0.20).
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Then we developed a full model by adjusting for the covariates, baseline disability, and
intervention group factor. All analyses were performed using SAS Version 9.1 (SAS
Institute, Cary, NC).
Results
Characteristics of the Sample
Table 1 shows baseline characteristics of the 274 participants with cancer-related pain, and
also compares those who completed the 12-month follow-up interview (completers) and
those who did not (non-completers). Completers were 66% in the 274 participants. Non-
completers were similar to completers except for being more socioeconomically
disadvantaged (P< 0.001), more likely to have lung or gastrointestinal cancer (P< 0.001),
and more likely to have a newly diagnosed or recurrent/progressive cancer (P< 0.001).
Importantly, baseline disability (SDS and TDD), pain (BPI severity), and depression
(HSCL-20) were not different between completers and non-completers. The completers
reported a mean of 4.31 (± 3.85) on the SDS at 12 months, and 50% (n = 90) reported TDD
≥ 14 days.
Research Question 1: Does Cancer-Related Pain in Cancer Survivors on Entry to the
INCPAD Trial (Baseline) Predict Disability at 12 Months?
The results of the linear regression model and logistic regression model are summarized in
Table 2. There was no relationship between baseline cancer-related pain and either of the
disability variables (SDS or TDD) at 12 months after controlling for the intervention group
factor, baseline disability, and covariates. Variables that did predict a higher SDS score at 12
months included greater baseline disability, worse depression, and more socioeconomic
disadvantage, whereas being in the intervention group predicted a lower SDS score.
Variables that predicted TDD ≥ 14 days at 12 months included greater baseline disability
and greater socioeconomic disadvantage. Other potential covariates not shown in Table 2
that were not significant included age, medical comorbidity, sex, race, marital status, type of
cancer, and phase of cancer.
Research Question 2: Do Changes in Cancer Survivors’ Cancer-Related Pain Predict
Subsequent Disability Over 12 Months?
Table 3 summarizes results from the linear mixed effects repeated measures and generalized
linear mixed effects repeated measures analyses. Change in pain severity was a significant
predictor of both disability outcomes. For each one-point decrease in BPI severity, the SDS
score decreased by 0.17, and there was a 15% decrease (i.e., odds ratio [OR] = 0.85) in the
likelihood of having 14 or more disability days in the past four weeks. Also, greater baseline
disability and worse depression predicted greater disability over 12 months, whereas being
in the intervention group predicted less disability.
Discussion
Our study findings can help inform cancer survivors and their family members, health care
providers, and employers who are concerned about disability resulting from cancer-related
symptoms such as pain. While baseline cancer-related pain was not a predictor of disability
at 12 months, change in pain over the 12 months did predict disability. Specifically,
improvement in pain resulted in less disability whether measured as a continuous disability
score or as categorical outcome (i.e., ≥ 14 disability days in the past four weeks).
Importantly, change in pain severity remained a predictor even after adjusting for baseline
disability, depression severity, and the effects of the intervention.
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Our study has several strengths. First, we focused on survivors with at least moderately
severe cancer-related pain, so we could readily observe changes in pain over a period of
time without a ceiling effect. Second, disability beyond physical dysfunction was measured.
We broadened our conceptual definition of disability to difficulty performing roles and
responsibilities in family, social life, and at work. We also used two measures to
operationalize disability: a continuous disability score (SDS) as well as a binary variable of
14 or more days in the past four weeks with at least a 50% reduction in usual activities
(TDD). Therefore, when a predictor variable or covariate predicted both outcomes, its
relationship with disability could be considered more robust because it was associated with
two perspectives on disability measures.
Not surprisingly, the intervention group, which received telecare management focused on
optimizing pain therapy, had less disability. Also, baseline disability was a predictor of
disability at 12 months as well as in the repeated measures analysis over the 12 months of
the INCPAD trial. This result was similar to that of a prior study that showed baseline
disability predicted disability at 24 months among older cancer survivors who had had no
active treatment for three years.10
Two other predictors of disability over 12 months were depression and socioeconomic
disadvantage. The substantial and pervasive effect of depression on disability is well-
established.39, 40 Our findings suggest in addition to treating pain, treating comorbid
depression may be beneficial in reducing disability. The reciprocal adverse effects of pain
and depression on one another as well as upon functional status and quality of life41–43 make
their co-management a clinical priority.
Some cancer studies have shown that lower educational attainment or household income
was associated with working disability.11, 44–46 Socioeconomically disadvantaged patients
may be more likely to use negative coping strategies, hold physically demanding jobs with
limited autonomy, possess little or no health insurance, and have less social support, which
may lead to greater disability.47 For cancer survivors who are disadvantaged
socioeconomically, clear and appropriate pain education, additional care management, and
supportive social services may be needed when a pain management intervention is
implemented. Referrals to social workers, public welfare agencies, and resources for cancer
survivors, such as the American Cancer Society, may be important to consider for this
subgroup of the population.
There are some limitations in our study. First, we used a sample of cancer patients in the
INCPAD study. This may limit the generalizability of the findings as patients had to meet
study eligibility criteria and agree to participate in the study. Second, we lost one-third
(34%) of participants over 12 months in the study. However, their baseline disability, pain,
and depression were not different from those who completed the study interview at 12
months.
Between 33% and 50% of patients experience cancer-related pain at some point in the
cancer trajectory.48 Our findings highlight the importance of effective pain management
among cancer survivors in potentially reducing long-term disability. Patients with high
disability at baseline may require extra efforts, as may those who are socioeconomically
disadvantaged or suffer from clinical depression. Recognizing the value of effective pain
treatment as well as clinical factors requiring special attention are significant steps towards
the alleviating the burden of cancer-related symptoms.
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Fig. 1.
Repeated measures for examining whether preceding cancer-related pain change predicts
subsequent disability over 12 months.
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Table 1
Baseline Characteristics of Participants with Cancer-Related Pain (T0)
n =274
(T0)
n =180
(12-month Completers)
n = 94
(12-month Non-completers)
Pa
M (SD) M (SD) M (SD)
Age 58.08 (10.54) 58.06 (10.39) 58.14 (10.87) 0.95
SED Index
(0–3 points)
1.30 (0.98) 1.15 (0.96) 1.60 (0.95) < 0.001
Medical Comorbidity
(No. of diseases)
2.09 (1.68) 2.17 (1.63) 1.93 (1.78) 0.25
Cancer-related Pain
(BPI, 0–10 scale)
5.22 (1.82) 5.18 (1.80) 5.30 (1.85) 0.59
Depression
(HSCL-20, 0–5 scale)
1.41 (0.76) 1.40 (0.78) 1.43 (0.74) 0.75
SDS
(0–10 scale)
5.43 (2.93) 5.28 (2.99) 5.72 (2.79) 0.24
n (%) n (%) n (%)
Group
  Intervention 137 (50) 91 (50.56) 46 (48.94) 0.80
Symptom Group
  Pain Only 96 (35.04) 66 (36.67) 30 (31.91) 0.43
Sex
  Female 181 (66.06) 126 (70.00) 55 (58.51) 0.06
Race
  White 212 (77.37) 142 (78.89) 70 (74.47) 0.41
Marital Status
  Married 130 (47.45) 85 (47.22) 45 (47.87) 0.92
Type of Cancer
  Breast 70 (25.55) 60 (33.33) 10 (10.64) < 0.001
  Lung 53 (19.34) 24 (13.33) 29 (30.85)
  Gastrointestinal 51 (18.61) 28 (15.56) 23 (24.47)
  Lymphoma or
    Hematological
40 (14.60)
27 (9.85)
28 (15.56)
18 (10.00)
12 (12.77)
9 (9.57)
  Genitourinary 33 (12.04) 22 (12.22) 11 (11.70)
  Other
Phase of Cancer
  Newly-diagnosed 104 (37.96) 60 (33.33) 44 (46.81) < 0.001
  Maintenance or disease-
    free
110 (40.15) 88 (48.89) 22 (23.40)
  Recurrent or
    progressive
60 (21.90) 32 (17.78) 28 (27.79)
TDD
  ≥ 14 days 186 (67.88) 124 (68.89) 62 (65.96) 0.62
  < 14 days 88 (32.12) 56 (31.11) 32 (34.04)
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BPI = Brief Pain Inventory; HSCL-20 = Hopkins Symptom Check List-20; SED Index = Socioeconomic Disadvantage Index; SDS = Sheehan
Disability Scale; TDD = Total Disability Days.
a
Comparisons between 12-month follow-up and no 12-month follow-up groups. P-value < 0.05 is in boldface.
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